Clene Inc. is a biopharmaceutical company that focuses on the development of nanotechnology-based therapies for neurodegenerative diseases. Its primary purpose is to innovate and advance treatment options for conditions such as multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. Founded on the principles of using clean-surfaced, highly catalytic nanocrystals, Clene Inc. strives to enhance cellular energy production, which is crucial for neuronal health and function. This company's work is particularly significant in the medical field, impacting the biotechnology and healthcare sectors by addressing unmet medical needs with novel treatment approaches. Through various clinical trials and research initiatives, Clene Inc. aims to bring groundbreaking solutions to market, potentially altering the landscape of neurotherapeutics. Based in the United States, Clene Inc. continues to push the boundaries of scientific innovation and plays a pivotal role in the pursuit of effective therapies for chronic and debilitating neurological conditions.